Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response
Keywords: 
Imatinib
Chronic myeloid leukemia
Bcr-Abl mutations
Drug resistance
Issue Date: 
2003
Publisher: 
Ferrata Storti Foundation
ISSN: 
1592-8721
Citation: 
Agirre X, Fontalba A, Andreu EJ, Odero MD, Larrayoz MJ, Montiel C, et al. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response. Haematologica 2003 Dec;88(12):1425-1426.

Files in This Item:
File: 
2004 Haem Xabi.pdf
Description: 
Size: 
22,78 kB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.